

REMARKS

Claims 88-90, 94, 118-120, 124, 135, 137-140, 142, 150, 152, 154-157, 160, 165-171, and 175-177 were previously allowed. The claims have been renumbered and reordered at the Examiner's request to facilitate completion of the reopened examination. The claims reflect the amendments made up to and through August 15, 2000.

Applicants respectfully request entry of the amendments and withdrawal of the outstanding rejections. Applicants' representative would appreciate the opportunity to talk with the Examiner, in person or by telephone, to discuss any remaining questions and facilitate the prosecution and allowance of the application or to place the case in better form for appeal.

The Commissioner is hereby authorized to charge any filing fees which may be required or credit any overpayment to Deposit Account No. 01-0519 in the name of Amgen, Inc. An original and one copy of this paper are enclosed.

Respectfully submitted,

Daniel R. Curry
Attorney for Applicants
Registration No: 32,727
Phone: (805) 447-8102

Please send all future correspondence to:

U.S. Patent Operations/DRC
Dept. 4300 M/S 27-4-A
AMGEN INC.
One Amgen Center Drive
Thousand Oaks, California 91320-1799